Work

HSR25-160: Evaluating Patient Characteristics, Treatment Patterns, Clinical Outcomes, and Health Care Resource Use in Pemigatinib-Treated Cholangiocarcinoma (CCA) Patients: A Focus on Cancer of Unknown Primary